Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 2
1994 2
1997 1
1998 2
1999 3
2000 2
2001 3
2002 1
2003 1
2004 4
2005 3
2006 3
2007 5
2008 3
2009 7
2010 4
2011 6
2012 9
2013 11
2014 5
2015 8
2016 7
2017 9
2018 11
2019 6
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

118 results
Results by year
Filters applied: . Clear all
Page 1
Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D; ASCEND investigators. Kapoor R, et al. Among authors: cadavid d. Lancet Neurol. 2018 May;17(5):405-415. doi: 10.1016/S1474-4422(18)30069-3. Epub 2018 Mar 12. Lancet Neurol. 2018. PMID: 29545067 Clinical Trial.
Cardiac apoptosis in severe relapsing fever borreliosis.
Londoño D, Bai Y, Zückert WR, Gelderblom H, Cadavid D. Londoño D, et al. Among authors: cadavid d. Infect Immun. 2005 Nov;73(11):7669-76. doi: 10.1128/IAI.73.11.7669-7676.2005. Infect Immun. 2005. PMID: 16239571 Free PMC article.
Spirochetal infections.
Cadavid D. Cadavid D. Handb Clin Neurol. 2010;96:179-219. doi: 10.1016/S0072-9752(09)96012-2. Epub 2010 Jan 19. Handb Clin Neurol. 2010. PMID: 20109682 Review. No abstract available.
Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial.
Cadavid D, Mellion M, Hupperts R, Edwards KR, Calabresi PA, Drulović J, Giovannoni G, Hartung HP, Arnold DL, Fisher E, Rudick R, Mi S, Chai Y, Li J, Zhang Y, Cheng W, Xu L, Zhu B, Green SM, Chang I, Deykin A, Sheikh SI; SYNERGY study investigators. Cadavid D, et al. Lancet Neurol. 2019 Sep;18(9):845-856. doi: 10.1016/S1474-4422(19)30137-1. Epub 2019 Jul 5. Lancet Neurol. 2019. PMID: 31285147 Clinical Trial.
p38α Regulates Expression of DUX4 in a Model of Facioscapulohumeral Muscular Dystrophy.
Rojas LA, Valentine E, Accorsi A, Maglio J, Shen N, Robertson A, Kazmirski S, Rahl P, Tawil R, Cadavid D, Thompson LA, Ronco L, Chang AN, Cacace AM, Wallace O. Rojas LA, et al. Among authors: cadavid d. J Pharmacol Exp Ther. 2020 Sep;374(3):489-498. doi: 10.1124/jpet.119.264689. Epub 2020 Jun 23. J Pharmacol Exp Ther. 2020. PMID: 32576599
Acute optic neuritis: Unmet clinical needs and model for new therapies.
Galetta SL, Villoslada P, Levin N, Shindler K, Ishikawa H, Parr E, Cadavid D, Balcer LJ. Galetta SL, et al. Among authors: cadavid d. Neurol Neuroimmunol Neuroinflamm. 2015 Jul 23;2(4):e135. doi: 10.1212/NXI.0000000000000135. eCollection 2015 Aug. Neurol Neuroimmunol Neuroinflamm. 2015. PMID: 26236761 Free PMC article. Review.
Antibiotics for the neurological complications of Lyme disease.
Cadavid D, Auwaerter PG, Rumbaugh J, Gelderblom H. Cadavid D, et al. Cochrane Database Syst Rev. 2016 Dec 8;12(12):CD006978. doi: 10.1002/14651858.CD006978.pub2. Cochrane Database Syst Rev. 2016. PMID: 27931077 Free PMC article. Review.
The rhesus model of Lyme neuroborreliosis.
Pachner AR, Gelderblom H, Cadavid D. Pachner AR, et al. Among authors: cadavid d. Immunol Rev. 2001 Oct;183:186-204. doi: 10.1034/j.1600-065x.2001.1830115.x. Immunol Rev. 2001. PMID: 11782257 Review.
118 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page